SCHEDULE: FMR LLC Discloses 5.1% Stake in CG Oncology Inc.
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported a 5.1% beneficial ownership stake in CG Oncology Inc. as of June 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 3,856,261 shares of CG Oncology Inc. common stock.
- This represents 5.1% of the total outstanding common stock of CG Oncology Inc.
- The investment is passive, acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- FMR LLC holds sole voting power over 3,854,166 shares and sole dispositive power over 3,856,261 shares.
- Abigail P. Johnson holds sole dispositive power over 3,856,261 shares.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by a reputable institutional investor like FMR LLC is generally viewed positively by the market, suggesting a degree of confidence in the company, even if it's not an active investment.
Positives
- A major institutional investor, FMR LLC, and its CEO, Abigail P. Johnson, have taken a significant 5.1% stake in CG Oncology Inc., potentially signaling confidence in the company's prospects.
Negatives
- No specific negative information is disclosed in this beneficial ownership report.
Risks
- This beneficial ownership report does not detail specific risks related to CG Oncology Inc.'s operations or financial health.
Future Outlook
This beneficial ownership report does not contain forward-looking statements or guidance regarding CG Oncology Inc.'s future performance or strategic outlook.
Management Comments
- The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing indicates a significant passive investment by a major asset manager in the oncology sector, which could be viewed as a vote of confidence in CG Oncology Inc.'s position within the biotechnology and healthcare industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a 5.1% stake may increase investor confidence and potentially attract further institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2023-05-23 | Effective date of Power of Attorney for Richard Bourgelas, authorizing signatures on behalf of FMR LLC and Abigail P. Johnson. |
| 2023-08-08 | Date of previous Schedule 13G filing by FMR LLC where the Power of Attorney was incorporated by reference. |
| 2025-06-30 | Date of event which requires filing of this statement, representing the reporting period end date for beneficial ownership. |
| 2025-08-05 | Date of filing of this Schedule 13G. |
Keywords
CG Oncology Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Oncology, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.